Squarepoint Ops LLC Kinnate Biopharma Inc. Transaction History

Squarepoint Ops LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$2.24 - $2.66 $79,856 - $94,829	-35,650 Reduced 60.59%	23,187 $61,000
Q4 2023 Feb 14, 2024	SELL	$1.07 - $2.5 $95,634 - $223,445	-89,378 Reduced 60.3%	58,837 $139,000
Q2 2023 Aug 14, 2023	BUY	$2.33 - $6.84 $345,340 - $1.01 Million	148,215 New	148,215 $449,000
Q4 2022 Feb 14, 2023	BUY	$5.26 - $12.19 $131,978 - $305,859	25,091 New	25,091 $153,000
Q2 2022 Aug 15, 2022	SELL	$7.43 - $13.0 $104,495 - $182,832	-14,064 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$7.73 - $17.99 $108,714 - $253,011	14,064 New	14,064 $158,000
Q3 2021 Nov 15, 2021	SELL	$17.81 - $24.87 $236,374 - $330,074	-13,272 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$22.19 - $31.55 $294,505 - $418,731	13,272 New	13,272 $309,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.